UTQ-26564-40557
1 vaccination
1 coded response
5 check-ins
1 free-text entry
1 call case
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 750 / TX
- Registered
- 2021-03-22
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-03-22
Registered in v-safe
-
2021-03-22
Dose 1 — Moderna
- 2021-03-26
- 2021-03-29
- 2021-04-05
- 2021-04-13
-
2022-03-22
Survey response — 12 months, dose 1MedDRA: Nasopharyngitis, Upper respiratory tract infection — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: Upper respiratory infections, colds, etc.MedDRA releases: 2024-11 · check-in free text available
-
2022-03-22
Report sent to call center — 12 months, dose 1Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prOutpatient clinic or urgent care clinic visit · 1 call case(s)
- 2022-03-23
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-03-22 | Moderna |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2022-03-22 | Unsuccessful |
Free text
Release 11 — 12 months, dose 1
Symptoms: Upper respiratory infections, colds, etc.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Nasopharyngitis | · | · | ✓ |
| SD | Upper respiratory tract infection | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release